Suzhou Ribo Life Science Co., Ltd is committed to the improvement of key technologies around siRNA therapeutic development. The liver targeting delivery technology and second-generation modification technology at the company have evolved to a level of maturation that supports rapid development of drug candidates to clinical stages. Based on the system, four compounds have been advanced into Phase II or Phase I clinical stage to date, thus have generated encouraging data about safety, efficacy, and translational properties of the system. Ribo has been investing great efforts and resources in the development of siRNA delivery technologies for extrahepatic tissues and organs, such as, tumor,central nervous system (CNS), lung, kidney and muscle, etc. In directions such as third-generation modification technology, multi-gene silencing technology, and innovative synthesis technology, Ribo has also carried out a lot of research and achieved interesting results.
siRNA modification is a very important key technology in improving the efficiency, durability, and safety of siRNA drugs. Naked or unmodified oligonucleotides not only are highly susceptible to degradation, but also can trigger different degrees of their off-target effects and/or immunogenicity. Based on a large number of experimental results and deep understanding experience, it was recognized that innovative combinations of different siRNA backbone modifications, ribose modifications, base modifications, or other modifications can greatly improve the druggability of siRNA candidates. RSC2.0(Ribo Stabilization Chemistry)is made based on such systematic studies on the mechanisms of siRNA degradation and stabilization and their correlation with potency and/or off-target effects. RSC2.0 technology has been granted its patents from major patent offices in the United States, Canada, Australia, and other important jurisdictions, making it one of the few companies globally to obtain patent authorization for the siRNA chemical modification platform. Suzhou Ribo Life Science Co., Ltd is committed to continuously exploring an optimized modification platform aiming for furthermore improved the efficiency, durability, and safety of their siRNA products.
The delivery systems based on the uptake of siRNA via interaction of conjugated N-acetylgalactosamine (GalNAc) with its receptor has tremendously accelerated the siRNA drug development for the treatment of diseases associated with any gene expression in hepatocytes. GalNAc-siRNA conjugates specifically bind to the asialoglycoprotein receptor (ASGPR) on the surface of hepatocytes and trigger fast endocytosis of the siRNA. This can result in highly specific and highly durable enrichment of the siRNA in hepatocytes. GalNAc-based System for liver TARgeting, named RIBO-GalSTARTM, is an siRNA liver targeting delivery technology that Suzhou Ribo Life Science Co., Ltd developed independently through efforts in the past decade. The patents of RIBO-GalSTARTM have been granted by the patent authorities in important territories such as China, the United States, etc, and the technology has been employed in the research and development of a full panel of siRNA drug candidates for various targets and indications related to gene expression in the liver. Four of the drug products have been advanced into the different clinical stages, among which the fastest products have entered the phase II. More differentiated innovative drugs are in preclinical and IND application stages.
Suzhou Ribo Life Science Co., Ltd has been investing great efforts and resources in the development of siRNA delivery technologies for extrahepatic tissues and organs, such as, tumor,central nervous system (CNS), lung, kidney and muscle, etc. Pipelines have been initiated in three therapeutic areas: Oncology,Renal Diseases, and Neruo-diseases.
Among these, RIBO-OncoSTAR TM (Oncology Specific TARgeting technology) is a proprietary siRNA tumor delivery technology developed independently by Ribo, which enables specific drug delivery to a variety of tumors. Ribo has made significant progress in the development of siRNA therapeutics and diagnostic projects targeting glioma based on RIBO-OncoSTARTM. Efforts are being accelerated to quickly advance towards clinical studies. RIBO-OncoSTARTM will be further explored for treatment of other cancer diseases, too.
| 婬片野外A片AAA毛片啊 | 日本强伦轩人妻中文字幕 | 免费av在线播放 | 美女搡BBB又爽又猛又黄www | 免费看无码一级A片放24小时 | 中文字幕无码A片一区在线观看 | 91精品麻豆人妻一区二区 | 久久无码人妻一区二区三区午夜免费 | 红桃Av色Av无人妻久 | 69人妻精品丰满熟女区 | 五月婷婷综合激情 | 91久久久久久久久 | 亚洲AV成人无码精品区 | 国产精品乱码一区二区 | 日本丰满无码一区久久 | 国产在线观看精品一区 | 久久精品一区二区三区四区 | 中文字幕日韩视频在线 | 精品人伦一区二区色婷婷 | 波多野结衣无码A片一二区 91精品人妻中文字幕色欲 | 专干老熟女200部播放 | 中文字幕巨乱亚洲高清A片28 | 亚洲无码AV一区二区 | 免费AV网站在线观看 | 欧美被狂躁高潮A片视频 | 欧亚成人A片一区二区 | 乱子伦国语真实视频 | 东方av影库在线观看 | 躁BBB躁BBB躁BBBBBB | 美女被操出白浆在线观看 | 色桃臀无码在线视频 | 91色视频免费观看 | 91色成人少妇无码精品 | 秘书丝袜人妻中文字幕 | 国产99在线观看 | 蜜桃av秘 无码一区二区 | 老司机午夜福利私人玩物 | 成人天码区免费A片 | 亚洲精品视频在线播放 | 亚洲AV永久无码精品国产精 |